Nektar Therapeutics traded at $3.75 this Friday July 1st, decreasing $0.05 or 1.32 percent since the previous trading session. Looking back, over the last four weeks, Nektar Therapeutics lost 2.46 percent. Over the last 12 months, its price fell by 78.08 percent. Looking ahead, we forecast Nektar Therapeutics to be priced at 3.65 by the end of this quarter and at 3.36 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,838.00 26.00 0.68% 3.79%
Eisai 5,825.00 0 0% -44.52%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
ALKERMES 30.53 0.74 2.48% 20.67%
Amgen 245.55 2.25 0.92% -1.27%
Astrazeneca 65.95 -0.12 -0.18% 8.49%
Baxter International 65.49 1.26 1.96% -19.90%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
Biogen 210.63 6.69 3.28% -39.60%
Bluebird Bio 4.28 0.14 3.38% -86.36%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Cara Therapeutics 8.62 -0.51 -5.59% -40.06%
Dr.Reddys Laboratories 4,390.00 35.55 0.82% -20.75%
Esperion Therapeutics 6.45 0.09 1.42% -68.52%
Exelixis 21.57 0.75 3.60% 18.13%
Gilead Sciences 62.36 0.55 0.89% -10.01%
GlaxoSmithKline 1,788.20 -14.40 -0.80% 24.68%
Halozyme Therapeutics 44.48 0.48 1.09% -4.18%
Immunogen 4.61 0.11 2.44% -28.30%
Incyte Corp 77.67 1.70 2.24% -7.07%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
Ironwood Pharmaceuticals 11.53 0 0% -8.35%
Karyopharm Therapeutics 4.73 0.22 4.88% -55.00%
Eli Lilly 324.71 0.48 0.15% 38.79%
MacroGenics 3.05 0.10 3.39% -89.37%
Merck & Co 92.42 1.25 1.37% 17.58%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Novartis 80.69 -0.96 -1.18% -4.57%
Pfizer 52.31 -0.12 -0.23% 31.66%
Roche Holding 319.35 -3.25 -1.01% -9.66%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Teva Pharmaceutical Industries Ltd 2,769.00 23.00 0.84% -13.25%
Xencor 28.86 1.49 5.44% -18.43%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%
US400 2296 26.97 1.19% -15.27%

Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.